Highlights•Donor lymphocyte infusion (DLI) provides a way to enhance the graft-versus-
leukemia effect.•GvHD represents the main toxicity after DLI.•Pre-DLI low disease burden …

Donor lymphocyte infusion (DLI) can produce durable remissions in patients with chronic
myelogenous leukemia (CML) who have a relapse after an allogeneic stem cell …

Donor leukocyte infusions (DLI) can reverse relapse of hematologic malignancy following
allogeneic hematopoietic stem cell transplant (HSCT) in some cases. Little is known …

PURPOSE Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed
may attain complete remissions when treated with transfusions of leukocytes obtained from …

The dose escalation of chemoradiotherapy that is achievable with stem cell transplantation
is often insufficient to eradicate malignancy, and an associated immune-mediated graft …

Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after
allogeneic stem cell transplantation (SCT). We treated seven patients with DLI for indolent …

The results of donor lymphocyte infusion (DLI) for treatment of relapse after bone marrow
transplantation (BMT) are reviewed. Durable complete remission can be achieved at the …

Abstract Purpose: Donor lymphocyte infusions (DLIs) provide effectivetherapy for patients
with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation …

The infusion of lymphocytes from the original marrow donor (donor lymphocyte infusions
[DLI]) is remarkably effective in treating chronic myeloid leukemia in relapse after allogeneic …

Purpose To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed
acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation …